Wockhardt Limited

INR 2,575

apshot of Wockhardt Net Sales Revenues (9M FY22) EBITDA (9M FY22) Profit after tax (9M FY22) INR 2,575 Cr 12 manufacturing facilities across world INR 331 Cr 3 R&D centres one each in India, UK, USA

INR 331

DA (9M FY22) Profit after tax (9M FY22) INR 2,575 Cr 12 manufacturing facilities across world INR 331 Cr 3 R&D centres one each in India, UK, USA INR 32 Cr Over 520 scientists with over 80 PhD’s; Dru

INR 32

Cr 12 manufacturing facilities across world INR 331 Cr 3 R&D centres one each in India, UK, USA INR 32 Cr Over 520 scientists with over 80 PhD’s; Drug Discovery team > 150 associates Net Debt-Equity Ra

20%

scovery team > 150 associates Net Debt-Equity Ratio 0.34x1 ~ 5,400 employees3 globally with over 20% employees4 based outside India International business >80%2 3,214 patents filed; 793 patents gra

80%

~ 5,400 employees3 globally with over 20% employees4 based outside India International business >80%2 3,214 patents filed; 793 patents granted Pharmaceuticals & API Vaccines Diabetes Biosimilars

24%

ctly confidential | Page 3 Financial highlights Net Sales Revenues in INR Cr. EBITDA in INR Cr. 24% YOY growth 2,844 2,708 2,575 245 331 FY 19-20 FY 20-21 9M FY 21-22 FY 19-20 -47 FY 20-21

INR 700

nce capital Strictly confidential | Page 4 Net Debt : Equity @ 0.34* Total Equity increased by >INR 700 Cr. ; Total Borrowings Reduction by > INR 1,000 Cr. Total Equity INR Cr. Total Borrowings INR Cr.

INR 1,000

et Debt : Equity @ 0.34* Total Equity increased by >INR 700 Cr. ; Total Borrowings Reduction by > INR 1,000 Cr. Total Equity INR Cr. Total Borrowings INR Cr.* 3,057 3,760 3,774 2,632 1,853 1,569

rs 2

Cash & cash equivalents and other Bank balances Strictly confidential | Page 5 Future Growth drivers 2 years growth drivers 1 2 3 Vaccines - Focus on COVID-19 Vaccines Diabetes Biosimilars for Emer

rs 1

and other Bank balances Strictly confidential | Page 5 Future Growth drivers 2 years growth drivers 1 2 3 Vaccines - Focus on COVID-19 Vaccines Diabetes Biosimilars for Emerging markets Re-organize

rs 2

Oxford COVID-19 Vaccine to UK Govt. Strictly confidential | Page 7 Growth drivers for next 2 years 2 Diabetes Biosimilars for Emerging markets Focus on Recombinant Human Insulin and Insulin Glargine